X
[{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Silence Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Medpace, Inc
Filters
Companies By Therapeutic Area
Details:
EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including Becker Muscular Dystrophy and Duchenne muscular dystrophy.
Lead Product(s):
Sevasemten
Therapeutic Area: Genetic Disease
Product Name: EDG-5506
Highest Development Status: Phase II
Product Type: Small molecule
Recipient:
Edgewise Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 26, 2023
Details:
MSP-2017 (etripamil), is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient.
Lead Product(s):
Etripamil
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: MSP-2017
Highest Development Status: Phase III
Product Type: Small molecule
Recipient:
Milestone Pharmaceuticals
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 17, 2022
Details:
This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.
Lead Product(s):
SLN360
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: SLN360
Highest Development Status: Phase I
Product Type: Large molecule
Recipient:
Silence Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 17, 2021